Lexaria Bioscience Fact Sheet

LEXARIA BIOSCIENCE CORP. NASDAQ: LEXX PRICE $4.03 52 WK RANGE $3.78—$12.50 AVG. VOLUME 309.263 SHARES OUTSTANDING 5.7 M MARKET CAP $23.1 M USD INSIDER OWNERSHIP 10% DRUG DELIVERY PLATFORM INNOVATOR Lexaria Bioscience Corp’s. (Nasdaq: LEXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through much more effective oral ingestion methods. The Company’s technology can be applied to many different ingestible product formats, including liquids, tablets, capsules, and more. DehydraTECH has repeatedly demonstrated with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes. In 2021, the Company is focused on three main areas: Antiviral drugs (including for potential use against COVID-19), CBD for Hypertension, and Oral nicotine dosing to replace smoking or vaping. Lexaria has licensed DehydraTECH to multiple companies, including Altria Corp for the development of smokeless, oral-based nicotine products. DehydraTECH is in widespread commercial use in the CBD industry for cannabinoid beverages, edibles, and oral products. Lexaria owns and operates a federally-licensed research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patent applications pending around the world. For more information, please visit www.lexariabioscience.com. Investment Highlights • Disruptive drug delivery technology with multiple opportunities for success in antivirals, nicotine, cannabinoids, and other Active Pharmaceutical Ingredients (“APIs”) • Revenue growth of more than 150% from 2020 to 2021 • Pharmacokinetic (“PK”) studies shown to deliver higher quantities of API in less time for: CBD for hypertension, Oral nicotine for reduced-risk and Antiviral drugs for COVID-19 and other infectious diseases • Up list to Nasdaq Capital Markets and raised US$11 million in January 2021; US$4 million raised in July 2021 • Investigational New Drug (IND) process begun for DehyrdaTECH-CBD as a prospective registered treatment for hypertension with the Food and Drug Administration (FDA) DehydraTECH™ • Patented formulation and dehydration processing method changes how the body detects and absorbs drugs • 23 patents granted (>50 pending) covering method-of-use, composition-of-matter and medical treatment claims  Patented DehydraTECH™ Process DehydraTECH™ Benefits Speeds up onset Increases bioavailability Improves drug potency Lower dosage Lower cost INVESTOR CONTACT Phone: 250-765-6424, ext. 202 ir@lexariabioscience.com Combine Active Pharmaceutical Ingredient with Fatty Acid Oil 1 Apply to food / carrier particles 2 Perform dehydration synthesis procedure 3 Render as powder or liquid for use in desired final form factor 4 Fatty Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, Canada www.lexariabioscience.com . i l i i i .

LEXARIA BIOSCIENCE CORP. NASDAQ: LEXX Pharmacokinetic comparsion of the ingestion of Turbo 90mg (soild circles; black), 90 mg (dashed open circles; black) and PTL101-100mg (dashed open squares; grey). Only mean data shown. PTL101-100mg data via gelatin matrix pellets, modified from Atsmon et al., 2018. DRUG DELIVERY PLATFORM INNOVATOR 2021/2022 Study Program • HYPER-A21-1 - Rodent study completed (n=10) demonstrating significant enhancement in CBD delivery using DehydraTECH - Up to 2,178% more CBD delivered into bloodstream and up to 1,737% more CBD delivered into brain tissue • HYPER-A21-2 - Rodent study completed (n=10) demonstrating strongest CBD absorption results ever recorded using DehydraTECH - New formulation delivers up to 2,708% more CBD into bloodstream • HYPER-H21-1 – Human clinical study (n=24) evidencing a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability • HYPER-H21-2 = Human clinical study (n=16) Hypoxic Pulmonary Vasoconstriction study; evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo and confirms DehydraTECH-CBD reduces arterial stiffness • VIRAL-C21-3 - In vitro screening assay completed using a primate cell line, VERO-E6, determined remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus • VIRAL-A20-2 - Rodent study completed (n=40) DehydraTECH enables up to three-fold increase in oral delivery of antiviral drugs, Remdesivir and Ebastine • VIRAL-MC21-1 - Successfully confirmed Lexaria's molecular characterization study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity ("NME") and that each drug tested remained stable and did not undergo change in chemical structure. These findings are strongly supportive of accelerated regulatory filings such as the 505(b)(2) pathway permitted by the Food and Drug Administration ("FDA") and other international regulators • VIRAL-A20-3 - Rodent PK study completed (n=20) demonstrating significant enhancement in antiviral drug delivery using DehydraTECH-enabled Colchicine. Possible benefits for treating SARS-CoV-2/COVID-19 and mRNA vaccine side effects • NIC-A21-1 - DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls Human Clinical Study: TurboCBD™ - Lexaria’s Oral CBD Product • Competitor delivers virtually zero CBD at 30 minutes • Lexaria quicker “on” and quicker “off” 0 10 20 30 40 50 60 BL 1 2 3 4 5 6 7 8 Plasma concentration (ng mL-1) Time (hours) Turbo 90 mg 90 mg PTL101 - 100 mg Lexaria Bioscience Corp. - #100-740 McCurdy Road - Kelowna, BC, Canada www.lexariabioscience.com INVESTOR CONTACT Phone: 250-765-6424 ext. 202 ir@lexariabioscience.com

LEXARIA BIOSCIENCE CORP. NASDAQ: LEXX DRUG DELIVERY PLATFORM INNOVATOR Additional 2022 DehydraTECH Investigations Cumulative Market Value Over $245 Billion Planned pharmacokinetic (“PK”) studies will evaluate DehydraTECH’s ability to improve quantity of drug delivered and speed with which it is delivered, in all of these areas: Size Future Size DehydraTECH Markets US $bn Year US $bn Year CBD 2.7 2021 111.0 2030 Cardiovascular Drugs 87.8 2020 107.8 2025 Antivirals 52.1 2021 66.7 2025 Oral Cannabinoid 18.4 2021 46.6 2025 Human Hormones 32.6 2020 46.5 2022 NSAIDs 17.1 2021 31.0 2031 Oral Mucosal Nicotine 19.6 2020 27.3 2028 Epilepsy 10.3 2020 16.6 2031 PDE5 Inhibitors 1.4 2020 5.9 2026 Nicotine Replacement 2.8 2020 3.9 2028 Vitamin D3 1.1 2021 1.7 2026 LEXARIA SUBSIDIARIES Lexaria Nicotine LLC (Majority-Owned) • Altria Group international license rights for undisclosed royalty • Research and Development agreement with British American Tobacco Lexaria Pharmaceutical Corp. (Wholly-Owned) • Programs commenced to prove delivery effectiveness in antiviral therapies for COVID-19/SARS-CoV-2 and other infectious diseases such as HIV, HSV, Influenza, EBV, HEP, CMV Lexaria Hemp Corp. (Wholly-Owned) • Clinically proven to increase rate and extent of orally ingested CBD (https://www.ncbi.nlm.nih.gov/pubmed/31512143) • Established North American partnerships generating revenues from DehydraTECH technology John Docherty, M.Sc., President & Director • Specialist in development of drug delivery technologies • Former President and COO of Helix BioPharma Corp. (TSX: HBP) • Named inventor on multiple issued and pending patents • Pharmacologist and toxicologist Chris Bunka, Chairman & CEO • Launched several successful private and public companies since the late 1980’s • Extensive experience in the capital markets, corporate governance, M&A and finance • Named inventor on multiple patent innovations MANAGEMENT Majority Interest Minority Interest + INVESTOR CONTACT Phone: 250-765-6424 ext. 202 ir@lexariabioscience.com Disclaimer: This fact sheet includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi ties Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities avai lable on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This fact sheet is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease. All supporting information for this fact sheet can be found at www.lexariabioscience.com.

RkJQdWJsaXNoZXIy NDMyMDk=